(CercleFinance.com) – Nanobiotix climbs 7% after the announcement of the presentation, at the annual meeting of the American Society for Clinical Oncology (ASCO), of new data highlighting the potential of NBTXR3 in combination with a chemotherapy.
In 12 patients with locally advanced stage IV head and neck cancer, a phase 1b/2 study showed that this combination had a favorable safety profile, a 100% disease control rate and an overall response rate of 58.3%.
In 31 evaluable patients with unresectable rectal cancer, a phase 1b/2 study showed it had a favorable safety profile, 100% disease control rate and overall response rate of 35.5%.